Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Uremia, a condition also known as uremic syndrome or azotemia, is caused by the build-up of waste products in the bloodstream due to kidney failure. The kidneys are responsible for removing toxins and excess fluids from the body, but when they stop functioning properly, these waste products accumulate and can cause a range of symptoms. These might include fatigue, loss of appetite, nausea and vomiting, confusion, seizures and even coma in severe cases. Uremia can affect people at any age but is more commonly observed in older individuals with pre-existing conditions such as diabetes or high blood pressure. If left untreated or unmanaged over time, it can lead to permanent damage to multiple organs throughout the body including the heart and brain.
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.
3.
Obesity linked to subsequent neoplasms in childhood cancer survivors
4.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
5.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
1.
Colon Cancer Staging: What You Need to Know
2.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
3.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
4.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
5.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge